The invention provides an
immune effector cell conversion
receptor, coding
nucleic acid of the
immune effector cell conversion
receptor, a
nucleic acid construct containing the coding
nucleic acid, animmune
effector cell capable of expressing the
immune effector cell conversion
receptor, a pharmaceutical composition containing one or more selected from the group consisting of the immune effectorcell conversion receptor, the coding nucleic acid, the nucleic acid construct and the
immune effector cell, a preparation method for the
immune effector cell capable of expressing the immune effectorcell conversion receptor, and an application of one or more selected from the group consisting of the
immune effector cell conversion receptor, the coding nucleic acid, the nucleic acid construct, theimmune
effector cell and the pharmaceutical composition in preparation of anti-
cancer drugs. According to the invention, through the interaction between the immune
effector cell conversion receptor and a
binding protein thereof, cells capable of expressing the immune
effector cell conversion receptor can be effectively stimulated; specifically, immune effector cells activate signaling of a downstream
intracellular CD3 zeta region and an STAT5
transcription factor signaling pathway mediated by a white
hormone receptor chain mediated STAT3
transcription factor and a CD3 zeta region STAT5 binding motif; proliferation and
continuation of the cells can be effectively promoted; and a novel method is provided for stimulating and amplifying the cells
in vivo and / or
in vitro.